These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26650078)

  • 1. Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis.
    Johansson KA; Memirie ST; Pecenka C; Jamison DT; Verguet S
    PLoS One; 2015; 10(12):e0142691. PubMed ID: 26650078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
    Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
    Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.
    Verguet S; Murphy S; Anderson B; Johansson KA; Glass R; Rheingans R
    Vaccine; 2013 Oct; 31(42):4902-10. PubMed ID: 23871824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis.
    Assebe LF; Kwete XJ; Wang D; Liu L; Norheim OF; Jbaily A; Verguet S; Johansson KA; Tolla MT
    Malar J; 2020 Jan; 19(1):41. PubMed ID: 31973694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis.
    Johansson KA; Strand KB; Fekadu A; Chisholm D
    Health Policy Plan; 2017 Apr; 32(3):376-383. PubMed ID: 27935798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia.
    Pecenka CJ; Johansson KA; Memirie ST; Jamison DT; Verguet S
    BMJ Open; 2015 May; 5(4):e006402. PubMed ID: 25941175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
    Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
    BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
    Lara C; De Graeve D; Franco F
    Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study.
    Portnoy A; Sweet S; Desalegn D; Memirie ST; Kim JJ; Verguet S
    Health Policy Plan; 2021 Jun; 36(6):891-899. PubMed ID: 33942850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
    Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
    East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
    Kim SY; Lee G; Goldie SJ
    BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
    Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
    Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.